ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMLX vs ABBV // EV/EBITDA & P/E VALUATION

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AMLX 0 — ABBV 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMLX ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 70.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.00% -64.00 ABBV /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 33.3x — TIE /valuation <GO>
Free Cash Flow Yield -3.43% 3.47% -6.90 ABBV /fcf-yield <GO>
Operating Margin — 24.60% — TIE /operating-margins <GO>
Net Profit Margin — 6.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — 8.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 ABBV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 65.1 -13.21 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 113.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.60B $513.86B -$510.26B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMLX REV ABBV REV AMLX GROSS % ABBV GROSS % AMLX FCF ABBV FCF
FY 2025 $0 $61.16B — 70.2% -$123.5M $17.82B
FY 2024 $87.4M $56.33B 93.2% 70.0% -$167.8M $17.83B
FY 2023 $380.8M $54.32B — — $11.9M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
ABBV // BETA 1.15